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ABSTRACT
Background The UK has poor lung cancer survival
rates and high early mortality, compared to other
countries. We aimed to identify factors associated with
early death, and features of primary care that might
contribute to late diagnosis.
Methods All cases of lung cancer diagnosed between
2000 and 2013 were extracted from The Health
Improvement Network database. Patients who died
within 90 days of diagnosis were compared with those
who survived longer. Standardised chest X-ray (CXR) and
lung cancer rates were calculated for each practice.
Results Of 20 142 people with lung cancer, those who
died early consulted with primary care more frequently
prediagnosis. Individual factors associated with early
death were male sex (OR 1.17; 95% CI 1.10 to 1.24),
current smoking (OR 1.43; 95% CI 1.28 to 1.61),
increasing age (OR 1.80; 95% CI 1.62 to 1.99 for age
≥80 years compared to 65–69 years), social deprivation
(OR 1.16; 95% CI 1.04 to 1.30 for Townsend quintile 5
vs 1) and rural versus urban residence (OR 1.22; 95% CI
1.06 to 1.41). CXR rates varied widely, and the odds of
early death were highest in the practices which
requested more CXRs. Lung cancer incidence at practice
level did not affect early deaths.
Conclusions Patients who die early from lung cancer
are interacting with primary care prediagnosis,
suggesting potentially missed opportunities to identify
them earlier. A general increase in CXR requests may
not improve survival; rather, a more timely and
appropriate targeting of this investigation using risk
assessment tools needs further assessment.
INTRODUCTION
The UK has poor lung cancer survival rates com-
pared to other countries,1–3 and this is partly
explained by differences in early mortality.2 In the
UK, patients normally consult their general practi-
tioner (GP) prior to a secondary care referral, and
so it is important to understand the factors in
primary care that might lead to late diagnosis and
consequent high early mortality from lung cancer.
We hypothesised that older, more socially
deprived and isolated males, would be less likely to
consult their GPs and, hence, would be at increased
risk of early death from lung cancer. Additionally,
we reasoned that people who were registered at
practices in areas of high lung cancer incidence
might be recognised earlier by their GPs, and that
GPs who, in general, requested more chest X-rays
(CXR), would identify and refer their patients
earlier, with more favourable outcomes.
To address these questions, we used a large
primary care dataset to identify patient and primary
care features associated with death-certiﬁcate-only
diagnoses and 30-day and 90-day mortality after a
diagnosis of lung cancer.
METHODS
Dataset
The Health Improvement Network (THIN) is a
computerised, longitudinal, primary care dataset,
which has been previously validated for lung
cancer outcomes in addition to other major
comorbid illnesses and exposures.4–11 All symp-
toms, medical diagnoses, prescriptions, investiga-
tions and results are entered into the computer
system either during a consultation with a GP or
following communication from secondary care.
Study population
Cases of lung cancer were extracted for the period
January 2000–January 2013. To ensure that these
were incident rather than prevalent, we excluded
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What is the key question?
▸ What are the individual risk factors for early
death from lung cancer in the UK, and are
there any primary care features which may
contribute to this?
What is the bottom line?
▸ Thirty per cent of patients with lung cancer
died within 90 days of diagnosis, with
increasing age, male sex, socioeconomic
deprivation, rural versus urban location and
current smoking all independently associated
with early death.
Why read on?
▸ This is the ﬁrst paper to look in detail at
reasons for the excess early lung cancer
mortality in the UK, highlighting that those
with poorer prognosis are interacting with
primary care before diagnosis and suggesting
missed opportunities to identify them earlier.
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patients who registered less than 12 months prior to their diag-
nosis date.
Date of diagnosis and death were used to calculate the pro-
portion of patients who died early (cases). This included people
whose date of diagnosis and date of death were the same (‘death
certiﬁcate only diagnoses’), and those who died within 30 or
90 days of diagnosis. Those who survived longer than 90 days
were our comparator group.
Covariate descriptions
Smoking status was deﬁned as current, ex, never or missing.12
Where there were multiple smoking records, the most recent
record was used, but excluding the 6 months before the diagno-
sis date, to exclude changes related to symptomatic disease. The
presence of comorbidities before lung cancer diagnosis was
identiﬁed using Read codes and weighted to calculate a
Charlson comorbidity index, using our established method.13–15
Townsend Index of deprivation, divided into quintiles, was
used as a measure of socioeconomic status. Social isolation was
deﬁned using the household variable in THIN which identiﬁes
people living at the same address. Where only one person had a
particular household identiﬁer they were deﬁned as living alone.
Since individuals living in different ﬂats or apartments within
the same building may be given the same household identiﬁer, if
there were greater than 10 people with the same household
identiﬁer they were classiﬁed as unknown. We also identiﬁed
urban versus rural residence, using a census-derived variable in
the dataset, which classiﬁed areas into those with >10 000 inha-
bitants (urban), town and fringe, rural and unknown.
Primary care consultations and CXRs
We identiﬁed all records of consultations in the prediagnosis
period, using codes which identiﬁed ‘face-to-face’ or telephone
consultations. Multiple entries on the same date were counted
as one consultation only. In previous work, we identiﬁed the
period of 0–4 months from diagnosis date as the period during
which GPs investigate people for lung cancer,12 so for our ana-
lysis we looked at the numbers of consultations in this time
period. Patients were then grouped as low (0–5), medium
(6–10), and high frequency consulters (>10). We identiﬁed all
CXR requests for cases and controls in the 0–4-months prior to
diagnosis. If there were multiple requests for the same person
we counted only one. We combined this with consultation fre-
quency to produce a composite variable indicating the number
of times an individual had consulted in primary care (low,
medium or high as described above) and also whether or not
they had a CXR requested by their GP during the 0–4-month
time period.
Practice level variables
We calculated annual standardised overall CXR requesting rates
for each primary care practice between 1 January 2010 and 31
December 2012 as a marker of their general propensity to order
CXRs. This time period was chosen as all practices included in
the analysis were contributing and the level of data complete-
ness was high. We standardised the rate of CXRs using the
THIN population structure on 1 July 2010. We also calculated
background lung cancer incidence rates as proxy markers of
exposure/awareness using the same process.
Statistical methods
Statistical analyses were performed using Stata/MP, V.12
(StataCorp LP) software. Ethical approval for the study was
provided by the Cegedim Strategic Data Medical Research
Scientiﬁc Review Committee (Ref 13–015).
We calculated the proportion of people who died immediately
(death-certiﬁcate-only diagnoses), within 30 days and within
90 days of their diagnosis within groups according to the demo-
graphic covariates, consultations and practice level variables
described above. Kaplan–Meier survival curve was plotted for
the whole population. Logistic regression was used to calculate
ORs for death-certiﬁcate-only diagnosis, 0–30-day mortality
(death certiﬁcate only +30) and 0–90-day mortality (death cer-
tiﬁcate only +90) within each of the variables described above
and listed in table 1. We looked at each variable individually ini-
tially, then included those which showed an association in the
univariate model (p<0.05) in the multivariate analysis.
Likelihood ratio testing was used for all tests of signiﬁcance.
Since CXR and lung cancer incidence quartiles were grouped
by practice, we explored the use of Huber’s method of robust
regression to allow for underestimates in the SE.16 There was
minimal change in ORs and 95% CIs, so the results of the ori-
ginal multivariate analysis are presented.
RESULTS
Descriptive statistics
There were 29 073 patients with lung cancer in the initial THIN
extract. We plotted the standardised CXR rates and those practices
with rates of <1/100 population seemed to be distinct outliers,
and so all patients registered with any of these 71 practices were
excluded from further analysis as it seemed likely to us that GPs
were not routinely coding the CXRs that they were requesting.
This left 23 233 records. A further 3053 records with missing
demographic data (year of birth, sex or invalid practice registration
dates) or missing lung cancer diagnosis dates were also excluded.
We also excluded 38 patients aged less than 30 years, as lung
cancer is rare in this age group and may reﬂect a slightly different
disease process. After these exclusions 20 142 cases of lung cancer
from 444 general practices were used for the analysis (ﬁgure 1).
Five per cent (1071) of the cohort had death-certiﬁcate-only
diagnosis, 10% (2036) died between 1 and 30 days of diagnosis,
and a further 15% died between 31 and 90 days of diagnosis
(table 1).
The Kaplan–Meier survival curve for the whole lung cancer
population (truncated at 2 years postdiagnosis) is shown in
ﬁgure 2.
Patient level variables
Overall, 57% (11 468) were male, with a median age at diagno-
sis of 72 years. Patients who were 80 years and over comprised
35% of the death-certiﬁcate-only group, 32% of the 1–30-day
mortality group and 26% of the 31–90-day group. People who
died early were more often current smokers (40% in the
death-certiﬁcate-only group; 43% in both 1–30-day and
31–90-day mortality groups; and 36% in the control group) but
less likely to be ex-smokers (35%, 38%, 45% and 50%, respect-
ively). The death-certiﬁcate-only group had the highest propor-
tion of never smokers (15%). More of those who died early
were from the most socially deprived Townsend quintile; most
marked in the death-certiﬁcate-only group (21% were in
Townsend quintile 5 compared with 17% of controls) (table 1).
ORs followed similar trends across each of the three early
death groups, so we elected to report results for the
death-certiﬁcate-only +90 group for the remainder of this
section. The univariate analysis for all groups is presented in
table 2, with the multivariate analysis results for all groups pre-
sented in table 3.
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Table 1 Demographics of the lung cancer population
Death certificate only Died 1–30 days Died 31–90 days Comparator group
1071 (%) 2036 (%) 2976 (%) 14 059 (%)
Age at diagnosis (years)
30–39 1 (0.09) 1 (0.10) 4 (0.13) 83 (0.59)
40–44 8 (0.75) 11 (0.54) 16 (0.54) 138 (0.98)
45–49 15 (1.40) 22 (1.08) 41 (1.38) 306 (2.18)
50–54 33 (3.08) 44 (2.16) 77 (2.59) 610 (4.34)
55–59 45 (4.20) 127 (6.24) 196 (6.59) 1194 (8.49)
60–64 74 (6.91) 197 (9.68) 335 (11.26) 1868 (13.29)
65–69 114 (10.64) 294 (14.44) 416 (13.98) 2202 (15.66)
70–74 173 (16.15) 312 (15.32) 523 (17.57) 2442 (17.37)
75–79 228 (21.29) 379 (18.61) 612 (20.56) 2410 (17.14)
>80 380 (35.48) 648 (31.83) 756 (25.40) 1806 (19.96)
Sex
Male 634 (59.20) 1174 (57.66) 1777 (59.71) 7883 (56.07)
Female 437 (40.80) 862 (42.34) 1199 (40.29) 6176 (43.93)
Townsend deprivation quintile
1 165 (15.41) 356 (17.49) 514 (17.27) 2510 (17.85)
2 190 (17.74) 392 (19.25) 550 (18.48) 2695 (19.17)
3 201 (18.77) 428 (21.02) 629 (21.14) 1855 (20.31)
4 269 (25.12) 435 (21.37) 659 (22.14) 3088 (21.96)
5 (most) deprived) 224 (20.92) 382 (18.76) 548 (18.41) 2453 (17.45)
Missing 22 (2.05) 43 (2.11) 76 (2.55) 458 (3.26)
Smoking status
Never smoker 158 (14.75) 194 (9.53) 226 (7.59) 1356 (9.65)
Ex-smoker 378 (35.29) 783 (38.46) 1330 (44.69) 7007 (49.84)
Current smoker 423 (39.50) 874 (42.93) 1272 (42.74) 5149 (36.62)
Missing 112 (10.46) 185 (9.09) 148 (4.97) 547 (3.89)
Charlson score
0 415 (38.75) 880 (43.22) 1260 (42.34) 6226 (44.28)
1 264 (24.65) 471 (23.13) 701 (23.56) 3435 (24.43)
2–3 297 (27.73) 488 (23.97) 768 (25.81) 3385 (24.08)
>4 95 (8.87) 197 (9.68) 247 (8.30) 1013 (7.21)
Consultations and CXR*
Low, no CXR 396 (36.97) 1032 (33.22) 913 (30.68) 3889 (27.66)
Medium, no CXR 208 (19.42) 513 (16.51) 404 (13.58) 1317 (9.37)
High, no CXR 180 (16.81) 478 (15.38) 328 (11.02) 1571 (11.17)
Low, CXR 111 (10.36) 486 (15.64) 688 (23.12) 4348 (30.93)
Medium, CXR 98 (9.15) 399 (12.84) 454 (15.26) 1937 (13.78)
High, CXR 78 (7.28) 199 (6.40) 189 (6.35) 997 (7.09)
Number in household
Lives alone 299 (27.92) 609 (29.91) 932 (31.32) 4157 (29.57)
>1 person 696 (64.99) 1313 (64.49) 1924 (64.65) 9405 (66.90)
Unknown 76 (7.10) 114 (5.60) 120 (4.03) 497 (3.54)
Urban vs rural
Urban 750 (70.03) 1437 (70.58) 2035 (68.38) 9468 (67.34)
Town and fringe 147 (13.73) 205 (10.07) 314 (10.55) 1411 (10.04)
Rural 74 (6.91) 116 (5.70) 152 (5.11) 684 (4.87)
Unknown 100 (9.34) 278 (13.65) 475 (15.96) 2496 (17.75)
Practice CXR quartile (per 100 population)
1–2.73 179 (16.71) 398 (19.55) 600 (20.16) 3108 (22.11)
2.74–3.84 144 (13.45) 451 (22.15) 661 (22.21) 3201 (22.77)
3.85–5.33 354 (33.05) 527 (25.88) 778 (26.14) 3635 (25.86)
≥5.34 394 (36.79) 660 (32.42) 937 (31.49) 4115 (29.27)
Practice lung cancer quartile (per 100 000 population)
<34.3 191 (17.83) 397 (19.50) 538 (18.08) 2653 (18.86)
34.3–49.56 262 (24.46) 568 (27.90) 774 (26.01) 3699 (26.31)
49.57–71.63 298 (27.82) 570 (28.00) 809 (27.18) 3710 (26.39)
≥71.64 320 (29.88) 501 (24.60) 855 (28.73) 3998 (28.44)
*0–4 months prediagnosis.
CXR, chest X-ray.
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Increasing age was strongly related to early death, with an
adjusted OR of 1.80 (95% CI 1.62 to 1.99), in people aged
≥80 years compared with those aged 65–69 years. Ex-smokers
were less likely to die early compared with never smokers;
adjusted OR 0.87 (95% CI 0.78 to 0.97). Current smokers had
increased mortality compared with never smokers (adjusted OR
1.43 (95% CI 1.28 to 1.61)), apart from a small reduction in
early deaths in current smokers in the death-certiﬁcate-only
group (adjusted OR 0.80 (95% CI 0.65 to 0.98)). Male sex con-
ferred poorer outcomes; OR 1.17 (95% CI 1.10 to 1.24).
Those with greatest levels of socioeconomic deprivation had
increased odds of early death compared to more afﬂuent sub-
jects (adjusted OR 1.16 (95% CI 1.04 to 1.30) for Townsend
quintile 5 compared with quintile 1). Rural versus urban loca-
tion was also associated with poorer prognosis (adjusted OR
1.22 (95% CI 1.06 to 1.41)). We found no evidence of an inde-
pendent association between early death and Charlson
comorbidity index, or living alone versus in a shared dwelling.
GP consultations and individual CXR requests
Patients who died within 90 days of diagnosis consulted their
GP more frequently than controls, with a median of ﬁve consul-
tations (IQR 3–8) versus 4 (IQR 2–6). Those in the
death-certiﬁcate-only group were least likely to have had a CXR
performed in primary care (27%), compared with 52% of con-
trols. In the multivariate analysis, the odds of early death were
lower in people who had a CXR performed in primary care,
regardless of the number of times they consulted their GP.
Within this group of patients who had a CXR performed, the
odds of early death increased as consulting frequency increased.
Medium consulters who did not have a CXR performed had
greatest overall odds of early death (table 3).
Practice level variables
Lung cancer rates
Background lung cancer rates varied greatly between regions,
with a median UK standardised rate of 53/100 000 population
(IQR 38/100 000–74/100 000). We found no association
between background lung cancer rate at the practice with which
the patient was registered and 90-day mortality, although there
was a small reduction in 30-day mortality in the group regis-
tered at a practice which had the highest background lung
cancer rate (OR 0.85 (95% CI 0.75 to 0.97) (table 3).
Practice CXR rates
Age and sex-standardised CXR rates also differed widely between
the practices (ﬁgure 3); with a median rate of 4 per 100 popula-
tion per year (IQR 3/100–6/100 population). ORs for early death
increased with increasing CXR quartile, even after adjustment for
covariates including background lung cancer rate. People regis-
tered at a practice with a high propensity to investigate (CXR quar-
tile 4) were 41% more likely to die early than those registered at
the lowest quartile practices (death-certiﬁcate-only +90-day OR
1.41 (1.29 to 1.55)) (table 3).
DISCUSSION
Our results show that 30% of patients with lung cancer died
within 90 days of their diagnosis. Increasing age, male sex,
socioeconomic deprivation, rural versus urban location and
current smoking, were all strongly and independently associated
with early death, although early death was less likely in
ex-smokers compared with never smokers. Those who died
early consulted their GP more frequently than those who did
not, and were less likely to have had a CXR performed by
primary care.
At a practice level, a higher CXR rate was not associated with
a reduction in early deaths; in fact, patients seen at these prac-
tices were more likely to have died early than those seen at prac-
tices with lower CXR rates. Practices with higher background
lung cancer rates do not seem to be any more likely to diagnose
their patients at an early enough point in the disease process to
impact on early mortality.
Strengths and weaknesses
This work is the ﬁrst large study looking in detail at how events
in primary care relate to early mortality in lung cancer. Previous
work has conﬁrmed that the validity of a lung cancer diagnosis
in primary care databases is good and representative of National
Cancer Registry data.11 17 The death-certiﬁcate-only group com-
prised 5.3% of the lung cancer population, which is broadly
similar to death-certiﬁcate-only diagnosis ﬁgures from EnglishFigure 2 Kaplan–Meier plot for the whole study population.
Figure 1 Flowchart of inclusion and exclusion criteria for the health
improvement network (THIN) dataset.
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Table 2 Univariate ORs for death-certificate-only, death certificate +30-day mortality and Death certificate +90-day mortality groups
OR
p Value (LRT)
OR
p Value
(LRT)
OR
p Value
(LRT)
Death-certificate-only
(95% CI)
Death certificate +30
(95% CI)
Death certificate
+90 (95% CI)
Age at diagnosis (years)
30–39 0.23 (0.03 to 1.69) 0.22 (0.07 to 0.70) 0.23 (0.10 to 0.50)
40–44 1.12 (0.54 to 2.34) 0.79 (0.49 to 1.29) 0.68 (0.46 to 0.99)
45–49 0.95 (0.55 to 1.64) 0.68 (0.48 to 0.98) 0.68 (0.52 to 0.88)
50–54 1.04 (0.70 to 1.56) 0.72 (0.56 to 0.93) 0.67 (0.56 to 0.82)
55–59 0.73 (0.51 to 1.04) 0.79 (0.66 to 0.96) 0.82 (0.71 to 0.95)
60–64 0.77 (0.57 to 1.03) 0.79 (0.67 to 0.93) 0.87 (0.77 to 0.98)
65–69 1 <0.001 1 <0.001 1 <0.001
70–74 1.37 (1.07 to 1.75) 1.05 (0.91 to 1.21) 1.10 (0.99 to 1.23)
75–79 1.83 (1.45 to 2.30) 1.29 (1.13 to 1.48) 1.35 (1.22 to 1.50)
>80 2.62 (2.11 to 3.25) 1.85 (1.63 to 2.10) 1.70 (1.54 to 1.88)
Sex
Male 1.14 (1.00 to 1.29) 1.06 (0.98 to 1.15) 1.12 (1.06 to 1.20)
Female 1 0.046 1 0.124 1 <0.001
Townsend deprivation quintile
1 1 0.001 1 0.003 1 0.001
2 1.07 (0.86 to 1.33) 1.04 (0.92 to 1.18) 1.02 (0.92 to 1.13)
3 1.07 (0.87 to 1.32) 1.05 (0.92 to 1.19) 1.07 (0.97 to 1.18)
4 1.33 (1.08 to 1.62) 1.09 (0.96 to 1.23) 1.07 (0.97 to 1.18)
5 1.39 (1.13 to 1.71) 1.17 (1.03 to 1.33) 1.14 (1.03 to 1.26)
Missing 0.73 (0.46 to 1.15) 0.71 (0.54 to 0.93) 0.75 (0.38 to 0.44)
Smoking status
Never smoker 1 <0.001 1 <0.001 1 <0.001
Ex-smoker 0.46 (0.38 to 0.56) 0.63 (0.55 to 0.71) 0.83 (0.75 to 0.93)
Current smoker 0.71 (0.58 to 0.85) 0.91 (0.80 to 1.03) 1.17 (1.05 to 1.30)
Missing 1.76 (1.35 to 2.28) 1.92 (1.61 to 2.30) 1.91 (1.63 to 2.24)
Charlson score
0 1 0.001 1 0.001 1 <0.001
1 1.15 (0.98 to 1.36) 1.03 (0.93 to 1.13) 1.02 (0.94 to 1.10)
2–3 1.32 (1.13 to 1.54) 1.09 (0.99 to 1.20) 1.12 (1.04 to 1.21)
>4 1.41 (1.11 to 1.78) 1.34 (1.16 to 1.54) 1.30 (1.16 to 1.45)
Consultations and CXR*
Low, no CXR 1 <0.001 1 <0.001 1 <0.001
Medium, no
CXR
1.41 (1.18 to 1.68) 1.39 (1.23 to 1.56) 1.39 (1.26 to 1.54)
High, no CXR 1.13 (0.94 to 1.35) 1.17 (1.04 to 1.32) 1.03 (0.93 to 1.13)
Low, CXR 0.28 (0.23 to 0.35) 0.45 (0.40 to 0.50) 0.54 (0.50 to 0.59)
Medium, CXR 0.50 (0.40 to 0.63) 0.78 (0.68 to 0.88) 0.88 (0.80 to 0.97)
High, CXR 0.82 (0.64 to 1.05) 0.78 (0.66 to 0.92) 0.78 (0.68 to 0.89)
Number in household
Lives alone 1 <0.001 1 <0.001 1 <0.001
>1 person 1.03 (0.89 to 1.18) 0.99 (0.91 to 1.08) 0.94 (0.88 to 1.01)
Unknown 2.13 (1.63 to 2.78) 1.73 (1.45 to 2.06) 1.41 (1.21 to 1.64)
Urban vs rural
Urban 1 <0.001 1 <0.001 1 <0.001
Town and fringe 1.32 (1.09 to 1.58) 1.07 (0.95 to 1.21) 1.06 (0.96 to 1.17)
Rural 1.37 (1.06 to 1.76) 1.07 (1.01 to 1.41) 1.12 (0.98 to 1.28)
Unknown 0.51 (0.41 to 0.63) 0.67 (0.60 to 0.75) 0.77 (0.70 to 0.84)
Practice CXR quartile (per 100 population)
1–2.73 1 <0.001 1 <0.001 1 <0.001
2.74–3.84 0.78 (0.62 to 0.98) 0.99 (0.88 to 1.12) 1.04 (0.94 to 1.14)
3.85–5.33 1.69 (1.40 to 2.04) 1.28 (1.15 to 1.44) 1.21 (1.01 to 1.32)
≥5.34 1.66 (1.38 to 2.00) 1.34 (1.20 to 1.50) 1.28 (1.17 to 1.39)
Practice lung cancer quartile (per 100 000 population)
<34.3 1 0.338 1 0.101 1 0.299
34.3–49.56 0.98 (0.81 to 1.19) 1.01 (0.90 to 1.13) 1.02 (0.93 to 1.12)
49.57–71.63 1.12 (0.92 to 1.35) 1.04 (0.93 to 1.17) 1.06 (0.97 to 1.17)
≥71.64 1.11 (0.92 to 1.34) 0.92 (0.82 to 1.03) 0.99 (0.90 to 1.08)
*0–4 months prediagnosis.
CXR, chest X-ray.
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Table 3 Multivariate ORs for death-certificate-only, death-certificate +30-day mortality and death certificate +90-day mortality groups
OR
p Value (LRT)
OR
p Value (LRT)
OR
p Value (LRT)
Death-certificate-only
(95% CI)
Death certificate +30
(95% CI)
Death certificate +90
(95% CI)
Age at diagnosis (years)
30–39 0.23 (0.03 to 1.71) 0.19 (0.06 to 0.61) 0.20 (0.09 to 0.45)
40–44 1.24 (0.59 to 2.61) 0.74 (0.45 to 1.22) 0.64 (0.43 to 0.94)
45–49 0.96 (0.55 to 1.67) 0.61 (0.43 to 0.88) 0.62 (0.48 to 0.81)
50–54 1.16 (0.77 to 1.73) 0.69 (0.53 to 0.89) 0.64 (0.53 to 0.78)
55–59 0.78 (0.55 to 1.11) 0.79 (0.65 to 0.95) 0.81 (0.70 to 0.94)
60–64 0.83 (0.62 to 1.12) 0.81 (0.69 to 0.96) 0.88 (0.78 to 1.00)
65–69 1 <0.001 1 <0.001 1 <0.001
70–74 1.38 (1.08 to 1.77) 1.07 (0.93 to 1.24) 1.13 (1.01 to 1.26)
75–79 1.73 (1.37 to 2.19) 1.30 (1.13 to 1.50) 1.39 (1.25 to 1.55)
>80 2.28 (1.83 to 2.85) 1.90 (1.66 to 2.16) 1.80 (1.62 to 1.99)
Sex
Male 1.21 (1.06 to 1.37) 1.12 (1.04 to 1.22) 1.17 (1.10 to 1.24)
Female 1 0.004 1 0.005 1 <0.001
Townsend deprivation quintile
1 1 <0.001 1 0.005 1 0.017
2 1.06 (0.85 to 1.32) 1.03 (0.90 to 1.18) 1.00 (0.91 to 1.11)
3 1.12 (0.90 to 1.39) 1.08 (0.95 to 1.23) 1.07 (0.96 to 1.18)
4 1.44 (1.17 to 1.78) 1.14 (1.00 to 1.30) 1.07 (0.96 to 1.18)
5 1.57 (1.25 to 1.97) 1.28 (1.11 to 1.47) 1.16 (1.04 to 1.30)
Missing 1.35 (0.82 to 2.22) 0.92 (0.68 to 1.25) 0.86 (0.69 to 1.08)
Smoking status
Never smoker 1 <0.001 1 <0.001 1 <0.001
Ex-smoker 0.48 (0.39 to 0.58) 0.66 (0.58 to 0.76) 0.87 (0.78 to 0.97)
Current smoker 0.80 (0.65 to 0.98) 1.14 (1.00 to 1.31) 1.43 (1.28 to 1.61)
Missing 1.31 (1.00 to 1.71) 1.85 (1.53 to 2.23) 1.89 (1.60 to 2.23)
Charlson score
0 1 0.125 1 0.168 1 0.234
1 1.17 (0.99 to 1.38) 1.02 (0.92 to 1.13) 0.96 (0.89 to 1.05)
2–3 1.20 (1.02 to 1.41) 1.03 (0.93 to 1.14) 1.02 (0.94 to 1.11)
>4 1.10 (0.87 to 1.41) 1.19 (1.02 to 1.38) 1.09 (0.97 to 1.24)
Consultations and CXR*
Low, no CXR 1 <0.001 1 <0.001 1 <0.001
Medium, no
CXR
1.43 (1.19 to 1.71) 1.43 (1.27 to 1.62) 1.43 (1.29 to 1.59)
High, no CXR 1.05 (0.86 to 1.27) 1.06 (0.94 to 1.21) 0.96 (0.86 to 1.06)
Low, CXR 0.28 (0.23 to 0.35) 0.45 (0.40 to 0.51) 0.54 (0.49 to 0.59)
Medium, CXR 0.50 (0.40 to 0.63) 0.80 (0.70 to 0.91) 0.90 (0.82 to 1.00)
High, CXR 0.88 (0.68 to 1.13) 0.83 (0.70 to 0.98) 0.81 (0.71 to 0.93)
Number in household
Lives alone 1 0.025 1 0.019 1 0.204
>1 person 1.17 (1.01 to 1.36) 0.035† 1.09 (1.00 to 1.19) 0.057† 1.01 (0.94 to 1.08) 0.912†
Unknown 1.39 (1.05 to 1.84) 1.28 (1.06 to 1.55) 1.16 (0.98 to 1.36)
Urban vs rural
Urban 1 <0.001 1 <0.001 1 <0.001
Town and
fringe
1.60 (1.32 to 1.95) 1.13 (0.99 to 1.28) 1.10 (0.99 to 1.22)
Rural 1.69 (1.30 to 2.20) 1.31 (1.10 to 1.56) 1.22 (1.06 to 1.41)
Unknown 0.50 (0.40 to 0.64) 0.68 (0.60 to 0.78) 0.79 (0.71 to 0.87)
Practice CXR quartile (per 100 population)
1–2.73 1 <0.001 1 <0.001 1 <0.001
2.74–3.84 0.71 (0.56 to 0.89) 0.96 (0.84 to 1.09) 1.03 (0.93 to 1.14)
3.85–5.33 1.72 (1.42 to 2.09) 1.38 (1.22 to 1.56) 1.28 (1.16 to 1.40)
≥5.34 1.78 (1.47 to 2.16) 1.52 (1.35 to 1.71) 1.41 (1.29 to 1.55)
Practice lung cancer quartile (per 100 000 population)
<34.3 1 0.522 1 0.009 1 0.064
34.3–49.56 0.92 (0.76 to 1.12) 0.97 (0.86 to 1.10) 0.98 (0.89 to 1.08)
49.57–71.63 1.05 (0.86 to 1.28) 1.02 (0.90 to 1.15) 1.05 (0.95 to 1.15)
≥71.64 1.01 (0.83 to 1.24) 0.85 (0.75 to 0.97) 0.93 (0.84 to 1.03)
*0–4 months prediagnosis.
†Excluding unknown.
CXR, chest X-ray
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Registry data,2 and lends weight to the validity of THIN as a
reliable source of lung cancer cases.
Data in THIN are prospectively recorded at the time of con-
sultation in primary care which minimises reporting and recall
bias, however, the information relies on accurate coding and
timely data entry in primary care. To minimise errors related to
this, we only used data entered by practices after the practice
met the THIN data quality and completeness standard. This
comprises a regular audit of the completeness of recording of
data related to a group of key conditions and exposures against
national ﬁgures.18
The principal limitation of this study is the lack of informa-
tion regarding stage, performance status, histology and interven-
tions in secondary care. We used early deaths as a marker of
people in whom lung cancer was diagnosed late, however, some
of these cases may have had early stage or completely asymp-
tomatic disease and died from other comorbid conditions,
although the relatively short interval between lung cancer diag-
nosis and death means that in the majority, underlying malig-
nancy is likely to be the main cause. There are additional
limitations with regard to variation in the quality and timeliness
of CXR reporting that could have inﬂuenced the apparently
higher proportion of early deaths in those practices with higher
CXR rates.
Other work in the literature
The International Cancer Benchmarking Project (ICBP) pro-
duced early mortality ﬁgures for four cancer sites (including
lung) for six countries.1 3 The 30-day mortality from lung
cancer in the UK ranged from 21% to 26% and was substan-
tially higher than in any of the other countries included (apart
from Ontario in Canada at 24%).1 They also showed, as we
have, that increasing age and male sex were associated with
early death, and other work has conﬁrmed this survival advan-
tage in women.19 Additionally, they suggested that smoking
habits may have a role to play, with the UK having a higher
prevalence of current smokers than some of the other counties
studied. 1 2 This is supported by our ﬁnding of a higher
proportion of early deaths in current smokers compared with
never or ex-smokers.
Current smoking at the time of diagnosis has been shown pre-
viously to predict poor prognosis. A study published by
Tammemagi and colleagues reported an adjusted HR for death
of 1.26 (95% CI 1.08 to 1.47) for current smokers versus ex or
never smokers.20 Additionally work looking at health beha-
viours suggests that ex-smokers are more likely to see themselves
as vulnerable to the adverse effects of smoking compared with
current smokers,21 and are, perhaps, more likely to be
health-aware leading to presentation earlier in the disease
process. This may explain our ﬁnding that they are less likely
than never smokers to die early.
Research from Leeds, England, looked at primary care CXR
referral rates over a 2-year period and showed, in a much
smaller sample, that there was marked variation in practice.
They found no correlation between practice CXR rates and lung
cancer survival (at 1 year).22
Interpretation of the results
Evidence presented in the National Cancer Intelligence
Network (NCIN) ‘Routes to Diagnosis’ work suggests that 39%
of lung cancer patients present via the emergency route, and
that these people have a much lower 1 year survival.23 It is
therefore not surprising that the proportion of patients who
died early who had a CXR requested by primary care was lower
than controls, and it seems likely that these people are diag-
nosed via an alternative route.
The National Institute for Health and Care Excellence
(NICE) referral guidelines24 give clear advice on speciﬁc symp-
toms which warrant a CXR and urgent referral. However, many
patients have a more non-speciﬁc presentation, which is often
attributed to other comorbid conditions. This may explain the
high numbers of consultations for some patients in the
4 months before diagnosis.
Higher CXR rates in general at practice level do not appear
to translate to reduction in early deaths from lung cancer; in
fact, people were more likely to die early from lung cancer if
Figure 3 Age and sex-standardised chest X-ray rates per 100 population in the general practitioner practices studied.
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they were registered at a practice that performed more CXRs.
This may be due in part to ascertainment bias, as performing
more CXRs means you are more likely to detect underlying
lung cancer in a terminally ill patient. This, in turn, highlights
that the burden of undiagnosed lung cancer is unknown.
We do not wish to imply that the CXR is not a useful initial
investigation in detection of symptomatic lung cancer. During
the Mayo Lung Project, mass screening study using CXRs, 90%
of peripheral cancers and 70% of central cancers were diag-
nosed after retrospectively reviewing ﬁlms.25 Like any investiga-
tion, however, it needs to be used at an appropriate time, in a
selected patient group.
Clinical relevance and conclusions
Patients who die early are interacting with primary care in the
run-up to diagnosis, suggesting that there are opportunities to
identify them earlier in the disease process. A general increase
in CXRs at primary care level is of questionable clinical and
cost effectiveness, and it is important to establish which inter-
ventions are likely to be useful at which point in the patient
pathway. It has been argued that better access to CT scanning in
primary care may be useful in reducing early deaths, however, it
may be that more timely and appropriate targeting of the CXR
remains the key. It seems clear that we need a greater focus on
older and socially deprived groups. At an individual GP level
lung cancer is rare; with each GP seeing on average one new
case per annum.26 For this reason, we need to promote better
use of risk assessment tools, 12 27–30 and use software prompts
to help GPs to identify and investigate, in a timely manner,
those at risk. This has potential to increase the proportion of
patients who are diagnosed at an early stage and are, therefore,
suitable for treatment with curative intent.
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